Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. (NasdaqCM:EBAC) from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million on October 17, 2022. The newly listed entity Oculis Holding SA will be a company registered in Switzerland with its headquarters at the current office of Oculis. The proposed transaction was unanimously approved by the board of directors of all parties and is supported by existing shareholders of Oculis. As of February 28, 2023, European Biotech Acquisition Corp. shareholders approved the deal. The proposed transaction is subject to, among other things, the approval by EBAC shareholders and the satisfaction or waiver of other customary closing conditions and is expected to be completed in the first half of 2023. As of February 28, 2023, the closing is expected to occur on or about March 2, 2023. BofA Securities is acting as financial advisor and SVB Securities is acting as capital market?s advisor to Oculis. Xander lee, Elizabeth Anne Wright, Patrick Van Eecke, Matthew Pavao, Natasha Leskovsek, Bronwyn l. Roberts, Jennifer Shanley, Katie Kazem, Michal Berkner, Div Gupta, Ryan Sansom and Aaron Pomeroy of Cooley (UK) LLP acted as US legal advisors, VISCHER SA serves as Swiss legal counsel and PricewaterhouseCoopers SA serves as auditors to Oculis, SA. Credit Suisse and Kempen are acting as financial advisor and capital markets advisor. Michael Davis, Derek Dostal, Corey M. Goodman, David R. Bauer and Jennifer S. Conway of Davis Polk & Wardwell LLP acted as U.S. legal advisors, Stibbe N.V. serves as Dutch legal counsel, and Maples Group serves as Cayman legal counsel to EBAC. Bill Nelson and Ilir Mujalovic of Shearman & Sterling LLP acted as legal advisor to Credit Suisse Securities (USA) LLC.
Oculis SA completed the acquition of European Biotech Acquisition Corp. (NasdaqCM:EBAC) from Lsp Sponsor Ebac B.V. and others in a reverse merger on March 2, 2023. As a result of the business combination, the common stock, warrant, and unit of European Biotech Acquisition Corp. (EBAC/W/U) will be suspended from trading.